Pune: Production of Covovax started at SII, shows 90.4 per cent efficacy

The statement added that the study enrolled at least 29,960 candidates across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity of the vaccine.

Novavax said that the Covovax vaccine had showed 93 per cent efficacy against predominantly circulating variants of concern and the variants of interest.

Advertisement

The firm announced on Friday that the manufacturing of the first batch of Covovax vaccine has started at Serum Institute of India, Pune facility.

The company said that a new milestone had been reached, they began their first batch of Covovax at their facility this week in Pune.

Adar Poonawalla, CEO of The Serum Institute of India said that they were hoping to launch Novavax’s COVID-19 vaccine “Covovax” in India by September as the trials of the vaccine have been in advanced stage of completion.

Novavax announced in September 2020 about a manufacturing agreement with SII for it’s COVID-19 vaccine NVX-CoV2373. Poonawalla said that the trial of Novavax’s coronavirus vaccine in India was likely to conclude by November. He added that the pharmacy giant could apply for a vaccine license even before it’s trial concludes in the country on the basis of the global data of the trial.

On June 14, Novavax said in a statement stated that a vaccine candidate ’NVX-CoV2373’ demonstrated 100 per cent protection against the moderate and severe COVID-19 infection, the candidate showed 90.4 per cent efficacy overall, it also met the primary endpoint in its PREVENT-19 picotal Phase 3 trial.

The statement added that the study enrolled at least 29,960 candidates across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity of the vaccine.

Novavax said that the Covovax vaccine had showed 93 per cent efficacy against predominantly circulating variants of concern and the variants of interest.